ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE

阿尔茨海默病神经影像计划

• 批准号: 8167083
• 负责人: GEORGE BARTZOKIS
• 金额: $ 0.26万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167083
• 关键词: Alzheimer' s Disease; Biological; Biological Markers; Canada; Clinical; Computer Retrieval of Information on Scientific Projects Database; Data; Development; Effectiveness; Evaluation; Frequencies; Funding; Grant; Image; Institution; Learning; Magnetic Resonance Imaging; Measures; Memory Loss; Monitor; Participant; Pharmaceutical Preparations; Positron-Emission Tomography; Recruitment Activity; Research; Research Personnel; Resources; Safety; Scanning; Site; Source; Staging; Testing; Time; United States National Institutes of Health; mild neurocognitive impairment; neuroimaging; neuropsychological

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a 5-year NIA initiative to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI will compare neuroimaging, biological and clinical information from study participants seeking correlations among the data that will track the progress of memory loss from its earliest stages. A total of 800 subjects will be recruited at 50 sites in the US and Canada. The subjects will undergo clinical and neuropsychological evaluations each time scanning is performed. All subjects will undergo repeated 1.5T MRI scanning, 25% will undergo repeated 3T MRI scanning, and 50% will undergo repeated PET scanning with the same frequency of scanning used for the 1.5T MRI imaging. What is learned from the study will be used to help researchers and clinicians develop new treatments and monitor their effectiveness, increasing safety and efficiency of medication development.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 阿尔茨海默病神经影像计划 (ADNI) 是一项为期 5 年的 NIA 计划，旨在测试是否可以将串行磁共振成像 (MRI)、正电子发射断层扫描 (PET)、其他生物标志物以及临床和神经心理学评估结合起来，以衡量阿尔茨海默病的进展情况。轻度认知障碍（MCI）和早期阿尔茨海默病（AD）。 ADNI 将比较研究参与者的神经影像、生物和临床信息，寻找数据之间的相关性，从而从最早阶段追踪记忆丧失的进展情况。 总共将在美国和加拿大的 50 个地点招募 800 名受试者。每次进行扫描时，受试者都将接受临床和神经心理学评估。所有受试者将接受重复的 1.5T MRI 扫描，25% 将接受重复的 3T MRI 扫描，50% 将接受重复的 PET 扫描，扫描频率与 1.5T MRI 成像相同。从研究中获得的信息将用于帮助研究人员和临床医生开发新的治疗方法并监测其有效性，从而提高药物开发的安全性和效率。